Shanghai Fosun Pharmaceutical (Group) Toekomstige groei

Future criteriumcontroles 3/6

Shanghai Fosun Pharmaceutical (Group) zal naar verwachting groeien in winst en omzet met respectievelijk 31.8% en 8.3% per jaar. De winst per aandeel zal naar verwachting groeien met 32.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 8.8% zijn.

Belangrijke informatie

31.8%

Groei van de winst

32.1%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	19.2%
Inkomstengroei	8.3%
Toekomstig rendement op eigen vermogen	8.8%
Dekking van analisten	Good
Laatst bijgewerkt	01 Nov 2024

Recente toekomstige groei-updates

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

May 01

Recent updates

Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Is Paying Out Less In Dividends Than Last Year

Aug 03

Here's Why Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Has A Meaningful Debt Burden

Jul 28

Market Still Lacking Some Conviction On Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196)

May 23

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

May 01

We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings

Apr 02

Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment?

Mar 18

Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%?

Feb 26

Winst- en omzetgroeiprognoses

SHSE:600196 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	49,202	4,466	N/A	5,976	5
12/31/2025	48,537	3,970	N/A	4,689	7
12/31/2024	41,612	2,808	N/A	3,725	2
9/30/2024	41,611	2,114	-207	3,939	N/A
6/30/2024	40,467	1,835	-976	3,511	N/A
3/31/2024	40,686	2,009	-1,430	3,458	N/A
12/31/2023	41,400	2,386	-1,922	3,414	N/A
9/30/2023	43,029	3,578	-2,095	3,535	N/A
6/30/2023	43,999	3,972	-2,007	4,229	N/A
3/31/2023	44,437	4,261	-1,858	4,235	N/A
12/31/2022	43,952	3,731	-1,671	4,218	N/A
9/30/2022	43,586	3,600	-1,882	4,066	N/A
6/30/2022	43,406	3,782	-1,252	4,030	N/A
3/31/2022	41,340	4,338	-1,140	4,057	N/A
12/31/2021	39,011	4,729	-1,035	3,938	N/A
9/30/2021	35,253	4,749	-1,525	3,142	N/A
6/30/2021	33,231	4,430	-1,994	2,825	N/A
3/31/2021	32,483	3,933	-1,748	2,934	N/A
12/31/2020	30,307	3,663	-1,857	2,580	N/A
9/30/2020	29,460	3,737	-1,021	3,347	N/A
6/30/2020	28,441	3,520	-592	3,234	N/A
3/31/2020	27,736	3,187	-552	3,197	N/A
12/31/2019	28,585	3,322	-740	3,222	N/A
9/30/2019	28,004	2,677	-449	3,191	N/A
6/30/2019	27,232	2,664	-893	3,122	N/A
3/31/2019	25,929	2,714	-875	2,892	N/A
12/31/2018	24,918	2,708	-225	2,950	N/A
9/30/2018	23,716	2,799	-55	2,945	N/A
6/30/2018	22,040	2,996	N/A	2,755	N/A
3/31/2018	20,372	3,092	N/A	2,644	N/A
12/31/2017	18,534	3,124	N/A	2,580	N/A
9/30/2017	16,951	3,047	N/A	2,310	N/A
6/30/2017	16,045	2,993	N/A	2,278	N/A
3/31/2017	15,283	2,908	N/A	2,128	N/A
12/31/2016	14,629	2,805	N/A	2,110	N/A
9/30/2016	14,173	2,745	N/A	1,983	N/A
6/30/2016	13,624	2,657	N/A	1,880	N/A
3/31/2016	13,034	2,557	N/A	1,822	N/A
12/31/2015	12,609	2,459	N/A	1,621	N/A
9/30/2015	12,438	2,429	N/A	1,519	N/A
6/30/2015	12,408	2,398	N/A	1,474	N/A
3/31/2015	12,168	2,234	N/A	1,376	N/A
12/31/2014	12,026	2,113	N/A	1,200	N/A
9/30/2014	11,587	2,207	N/A	1,388	N/A
6/30/2014	11,026	1,987	N/A	1,104	N/A
3/31/2014	10,598	1,646	N/A	942	N/A
12/31/2013	9,996	1,583	N/A	1,012	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 600196 ( 31.8% per jaar) ligt boven de spaarquote ( 2.9% ).

Winst versus markt: De winst van 600196 ( 31.8% per jaar) zal naar verwachting sneller groeien dan de CN markt ( 25.9% per jaar).

Hoge groeiwinsten: De winst van 600196 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van 600196 ( 8.3% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 14% per jaar).

Hoge groei-inkomsten: De omzet van 600196 ( 8.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 600196 zal naar verwachting over 3 jaar laag zijn ( 8.8 %).

Shanghai Fosun Pharmaceutical (Group) Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 12%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

Consensus EPS estimates fall by 17%

Price target decreased by 13% to CN¥32.65

Price target decreased by 7.0% to CN¥37.41

Consensus forecasts updated

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 24%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Election of Chen Yuqing as Non-Executive Director

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces in Relation to the Approval for Drug Registration of Licensed Product

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Is Paying Out Less In Dividends Than Last Year

Dividend reduced to CN¥0.27

Here's Why Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Has A Meaningful Debt Burden

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Board and Board Committee Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 23 August 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive and Committee Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 26, 2024

Market Still Lacking Some Conviction On Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196)

Consensus EPS estimates fall by 12%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

First quarter 2024 earnings: EPS and revenues miss analyst expectations

We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings

Consensus EPS estimates fall by 17%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Profit margin trend

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023

Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment?

Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%?

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) acquired additional 40% stake in Shanghai Fujian Equity Investment Fund Management Co., Ltd. from Shanghai Fosun Health Industry Holding Company Limited for CNY 22.2 million.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Jiangsu Xingsheng Xinhui Pharmaceutical Co., Ltd. Receives Approval from the National Medical Products Administration of China for the Clinical Trial of XS-03 Tablets

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that it expects to receive CNY 497.7664 million in funding

Price target decreased by 13% to CN¥32.65

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces National Medical Products Administration Accepts New Drug Application of Cisplatin Injection

Price target decreased by 7.0% to CN¥37.41

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.42 in 2Q 2022)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2023 Results on Aug 29, 2023

Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Approval for Drug Registration of Fosun Kite Biotechnology Co., Ltd

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 28, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

Fosun Reportedly Planning Sale of Gland Pharma

China's Fosun Reportedly Said to Mull Sale of India's $3.6 Billion Gland Pharma

Less than half of directors are independent

Consensus forecasts updated

Investor sentiment improved over the past week

Shandong Liancheng Precision Manufacturing Co., Ltd (SZSE:002921) completed the acquisition of 3.9858% stake in Shanghai Shen-li High Tech Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) and Shanghai Fulian Technology Co., Ltd.

Third quarter 2022 earnings: Revenues exceed analyst expectations

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2022 Results on Oct 28, 2022

Executive Vice Chairman recently bought CN¥391k worth of stock

Now 20% undervalued after recent price drop

Executive Chairman recently bought CN¥887k worth of stock

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2022 Results on Aug 29, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Appoints Wen Deyong as an Executive Director

Price target decreased to CN¥46.32

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive Appointments

Price target decreased to CN¥50.41

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Recommends Final Dividend for 2021, Dispatch of Cheques for the 2021 Final Dividend Payable on H Shares Is 4 July 2022

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to CN¥56.55

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2022 Results on Apr 26, 2022